CN108752318A - 一种多氟取代芳联杂环类化合物的晶型、制备方法和应用 - Google Patents
一种多氟取代芳联杂环类化合物的晶型、制备方法和应用 Download PDFInfo
- Publication number
- CN108752318A CN108752318A CN201810756914.9A CN201810756914A CN108752318A CN 108752318 A CN108752318 A CN 108752318A CN 201810756914 A CN201810756914 A CN 201810756914A CN 108752318 A CN108752318 A CN 108752318A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- preparation
- structural formula
- compound
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 108
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- -1 heterocycle compound Chemical class 0.000 title claims abstract description 13
- 238000006467 substitution reaction Methods 0.000 title claims abstract description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- 235000019441 ethanol Nutrition 0.000 claims description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 238000002425 crystallisation Methods 0.000 claims description 10
- 150000002576 ketones Chemical class 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 8
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- 238000005286 illumination Methods 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 description 60
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000002411 thermogravimetry Methods 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 11
- 108091008611 Protein Kinase B Proteins 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 6
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000004455 differential thermal analysis Methods 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229940126638 Akt inhibitor Drugs 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100037709 Desmocollin-3 Human genes 0.000 description 2
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 101150045355 akt1 gene Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 229940116298 l- malic acid Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000003197 protein kinase B inhibitor Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- 101150051155 Akt3 gene Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BJFGYRZTKQFTJT-WMZHIEFXSA-N C[n]1nccc1C(CC1)=CC(CC=C)=C1C(N[C@H](CNCC1)[C@@H]1c(cc1F)ccc1F)=O Chemical compound C[n]1nccc1C(CC1)=CC(CC=C)=C1C(N[C@H](CNCC1)[C@@H]1c(cc1F)ccc1F)=O BJFGYRZTKQFTJT-WMZHIEFXSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- DRAIDCWRLMLTPH-UHFFFAOYSA-N Fc1ccccs1F Chemical compound Fc1ccccs1F DRAIDCWRLMLTPH-UHFFFAOYSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000968043 Homo sapiens Desmocollin-1 Proteins 0.000 description 1
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810756914.9A CN108752318B (zh) | 2018-07-11 | 2018-07-11 | 一种多氟取代芳联杂环类化合物的晶型、制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810756914.9A CN108752318B (zh) | 2018-07-11 | 2018-07-11 | 一种多氟取代芳联杂环类化合物的晶型、制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108752318A true CN108752318A (zh) | 2018-11-06 |
CN108752318B CN108752318B (zh) | 2020-05-12 |
Family
ID=63973241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810756914.9A Active CN108752318B (zh) | 2018-07-11 | 2018-07-11 | 一种多氟取代芳联杂环类化合物的晶型、制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108752318B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104926788A (zh) * | 2014-03-22 | 2015-09-23 | 浙江大学 | 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
CN108341801A (zh) * | 2017-01-24 | 2018-07-31 | 浙江大学 | 多氟取代芳联杂环类衍生物、含其的药物组合物及其应用 |
-
2018
- 2018-07-11 CN CN201810756914.9A patent/CN108752318B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104926788A (zh) * | 2014-03-22 | 2015-09-23 | 浙江大学 | 取代哌啶类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
EP3124486A1 (en) * | 2014-03-22 | 2017-02-01 | Zhejiang University | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof |
CN108341801A (zh) * | 2017-01-24 | 2018-07-31 | 浙江大学 | 多氟取代芳联杂环类衍生物、含其的药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108752318B (zh) | 2020-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11098015B2 (en) | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | |
CN111187253B (zh) | 一种阿昔替尼新晶型 | |
WO2016127074A1 (en) | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors | |
WO2015058589A1 (zh) | 吡啶酮类衍生物、其制备方法及其在医药上的应用 | |
TW201402563A (zh) | 一種酪胺酸激酶抑制劑的二馬來酸鹽的第i型結晶及製備方法 | |
US10208065B2 (en) | Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof | |
WO2018117267A1 (ja) | 置換ピペリジン化合物の塩 | |
TW202208375A (zh) | 4-胺基-5-(6-(4-甲基哌-1-基)-1h-苯并[d]咪唑-2-基)噻吩并[2,3-b]吡啶-6(7h)-酮之鹽及晶形 | |
TWI705060B (zh) | 一種mek激酶抑制劑的對甲苯磺酸鹽、其結晶形式及製備方法 | |
WO2016136928A1 (ja) | イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法 | |
WO2023071314A1 (zh) | Shp2与cdk4/6双靶点抑制化合物合成及其制备方法与应用 | |
US9884856B2 (en) | Crystal form of Dabrafenib mesylate and preparation method thereof | |
WO2016101867A1 (zh) | 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物 | |
WO2021000687A1 (zh) | Pac-1晶型的制备方法 | |
CN108752318A (zh) | 一种多氟取代芳联杂环类化合物的晶型、制备方法和应用 | |
TW202317098A (zh) | 一種egfr抑制劑的多晶型 | |
WO2022063229A1 (zh) | 含芳氨基喹唑啉的化合物的盐及其制备方法和应用 | |
CN111601791B (zh) | Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
CN109705090B (zh) | 3,4-二取代的1h-吡唑化合物的酒石酸加成盐及其晶型 | |
WO2018177276A1 (zh) | 一种微管蛋白抑制剂的a晶型 | |
WO2023072263A1 (zh) | 5-取代的吡啶-2(1h)-酮类化合物及其应用 | |
TWI815472B (zh) | 一種激酶抑制劑的鹽晶型和自由鹼晶型 | |
WO2021143819A1 (zh) | 多环类间变性淋巴瘤激酶抑制剂的晶型 | |
CN108912035B (zh) | 一种具备抗肿瘤活性的吲哚酰胺类化合物 | |
TWI707853B (zh) | 1,2-二氫-1,6-萘啶類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210104 Address after: 510000 5th floor, building B5, 11 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee after: GUANGZHOU LIXIN PHARMACEUTICALS Co.,Ltd. Address before: 310027 No. 38, Zhejiang Road, Hangzhou, Zhejiang, Xihu District Patentee before: ZHEJIANG University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211224 Address after: 510000 Room 501, building B5, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong Patentee after: Guangzhou Lixin Biotechnology Co.,Ltd. Address before: 510000 5th floor, building B5, 11 Kaiyuan Avenue, Huangpu District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU LIXIN PHARMACEUTICALS CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230615 Address after: 510000 Room 501, building B5, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong Patentee after: GUANGZHOU LIXIN PHARMACEUTICALS CO.,LTD. Address before: 510000 Room 501, building B5, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong Patentee before: Guangzhou Lixin Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230824 Address after: 510000 Room 501, building B5, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong Patentee after: Guangzhou Lixin Biotechnology Co.,Ltd. Address before: 510000 Room 501, building B5, No. 11, Kaiyuan Avenue, Huangpu District, Guangzhou, Guangdong Patentee before: GUANGZHOU LIXIN PHARMACEUTICALS CO.,LTD. |